Ignite Creation Date:
2024-05-19 @ 5:33 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06413108
Status:
RECRUITING
Last Update Posted:
2024-05-14
First Post:
2024-05-03
Brief Title:
Safety Pharmacokinetics and Plasmodium Falciparum Transmission-reducing Activity of Monoclonal Antibody TB31F in Mali
Sponsor:
Radboud University Medical Center
Organization:
Radboud University Medical Center
Study Overview
Official Title:
A Phase 12a Single Centre Randomised Placebo-controlled Double-blind Dose-escalation Age De-escalation Study to Evaluate the Safety Tolerability Pharmacokinetics and Plasmodium Falciparum Transmission-reducing Activity of Monoclonal Antibody TB31F in Malaria-exposed Malian Adults and Children
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Mali faces a significant challenge with malaria particularly among its younger population While existing measures like seasonal chemoprevention and vaccination have shown efficacy further innovations are necessary to combat this disease The monoclonal antibody TB31F shows promise in reducing the transmission of malaria This clinical trial will evaluate the safety and efficacy of the monoclonal antibody TB31F
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None